Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Projektinformationen

SHIGETECVAX

ID Finanzhilfevereinbarung: 815568

DOI 10.3030/815568

EK-Unterschriftsdatum 30 April 2019

Startdatum 1 September 2019

Enddatum 28 Februar 2025

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 0,00

EU-Beitrag € 8 603 989,93

Koordiniert durch

EUROPEAN VACCINE INITIATIVE E.V
Germany

Leistungen

Open Research Data Pilot (1)

ORPD: Open Research Data Pilot

tbc

Documents, reports (1)

Composition of the SEAC incl. an ethics advisor

Composition of the SEAC incl an ethics advisor

Websites, patent fillings, videos etc. (1)

SHIGETECVAX web site

SHIGETECVAX web site established and launched

Veröffentlichungen

Peer reviewed articles (1)

Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

Autoren: Girardi, Petra, Shushan Harutyunyan, Irene Neuhauser, Katharina Glaninger, Orsolya Korda, Gábor Nagy, Eszter Nagy, Valéria Szijártó, Denes Pall, Krisztina Szarka, Gábor Kardos, Tamás Henics, and Frank J. Malinoski
Veröffentlicht in: Vaccines, 2022, ISSN 2076-393X
Herausgeber: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines10020340